3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Oxaliplatin
197
Bevacizumab
161
Fluorouracil
154
Capecitabine
137
Gemcitabine
134
Leucovorin
111
pembrolizumab
99
Cisplatin
94
Drug Therapy
89
Irinotecan
80
Radiotherapy
73
sintilimab
70
130-nm albumin-bound paclitaxel
66
durvalumab
65
Paclitaxel
64
Specimen Handling
62
Cetuximab
61
lenvatinib
59
tislelizumab
58
Nivolumab
55
Magnetic Resonance Spectroscopy
55
Folfox protocol
55
Blood Specimen Collection
52
atezolizumab
47
Biopsy
46
Surgical Procedures, Operative
40
Taxes
39
Albumin-Bound Paclitaxel
39
Immune Checkpoint Inhibitors
37
HMPL-013
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
gadoterate meglumine
×
Gastrointestinal
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled